ASCO has issued a new practice guideline update on the use of biomarkers in the management of metastatic breast cancer.1 The updated guideline revisits recommendations from the 2015 guideline and addresses topics that have emerged since then in the move toward personalized medicine in metastatic breast cancer.2

Key Points:

• ASCO has issued a new practice guideline update on the use of biomarkers in the management of metastatic breast cancer. The updated guideline makes a total of 11 recommendations, including in cases in which the Expert Panel found insufficient evidence to recommend routine testing for specific biomarkers.
• The Expert Panel found the strongest support for widespread testing for PIK3CAsomatic variants, germline BRCA1/2mutations, and PD-L1 expression.
• Using the correct assay for each biomarker is an important part of treatment planning and is becoming increasingly complicated. Commercial assays that test for multiple biomarkers simultaneously are easy to use but not appropriate in all instances. Oncologists should consult pathologists as needed.

Read more: https://dailynews.ascopubs.org/do/10.1200/ADN.22.201074/full/